NasdaqCM:CELC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	62	-147	-44	-204	6
12/31/2025	4	-143	-49	-156	7
12/31/2024	N/A	-99	-45	-65	7
6/30/2024	N/A	-83	-67	-66	N/A
3/31/2024	N/A	-73	-58	-58	N/A
12/31/2023	N/A	-64	-54	-54	N/A
9/30/2023	N/A	-57	-45	-45	N/A
6/30/2023	N/A	-49	-41	-41	N/A
3/31/2023	N/A	-45	-43	-43	N/A
12/31/2022	N/A	-41	-36	-36	N/A
9/30/2022	N/A	-36	-33	-33	N/A
6/30/2022	N/A	-31	-27	-27	N/A
3/31/2022	N/A	-35	-24	-24	N/A
12/31/2021	N/A	-30	-20	-20	N/A
9/30/2021	N/A	-25	-16	-16	N/A
6/30/2021	N/A	-22	-14	-14	N/A
3/31/2021	N/A	-10	-8	-8	N/A
12/31/2020	N/A	-9	-7	-7	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-8	-7	-7	N/A
3/31/2020	N/A	-8	-7	-6	N/A
12/31/2019	N/A	-7	-6	-6	N/A
9/30/2019	N/A	-7	-6	-6	N/A
6/30/2019	N/A	-7	-7	-6	N/A
3/31/2019	N/A	-7	-7	-6	N/A
12/31/2018	N/A	-7	-7	-6	N/A
9/30/2018	N/A	-7	-6	-6	N/A
6/30/2018	N/A	-7	-6	-6	N/A
3/31/2018	N/A	-7	N/A	-5	N/A
12/31/2017	N/A	-6	N/A	-5	N/A
9/30/2017	N/A	-5	N/A	-5	N/A
6/30/2017	N/A	-5	N/A	-4	N/A
3/31/2017	N/A	-4	N/A	-3	N/A
12/31/2016	N/A	-3	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CELC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CELC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CELC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CELCの収益 ( 68.5% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: CELCの収益 ( 68.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CELCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Celcuity 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 7.7% to US$29.50

Price target increased by 11% to US$27.40

Price target decreased to US$24.00

Price target decreased to US$30.50

Recent updates

Is Celcuity (NASDAQ:CELC) Using Too Much Debt?

Celcuity Inc. to Report Q2, 2024 Results on Aug 14, 2024

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Celcuity Inc. has completed a Follow-on Equity Offering in the amount of $60.0005 million.

New major risk - Shareholder dilution

Celcuity Inc. Announces Plan to Initiate A Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Celcuity Inc. to Report Q1, 2024 Results on May 15, 2024

Does Celcuity (NASDAQ:CELC) Have A Healthy Balance Sheet?

Price target increased by 7.7% to US$29.50

Celcuity Inc., Annual General Meeting, May 09, 2024

Celcuity Inc. to Report Q4, 2023 Results on Mar 27, 2024

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

Price target increased by 11% to US$27.40

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

New major risk - Revenue and earnings growth

Celcuity Inc. to Report Q3, 2023 Results on Nov 13, 2023

Celcuity Inc. announced that it expects to receive $50 million in funding

Celcuity Inc. Announces Plan to Conduct Phase 1B/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

New major risk - Revenue and earnings growth

Celcuity Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Celcuity (NASDAQ:CELC) Using Too Much Debt?

Independent Director recently bought US$103k worth of stock

Celcuity Inc. to Report Q1, 2023 Results on May 15, 2023

Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

Celcuity to Present Additional Data for Gedatolisib At the 2022 San Antonio Breast Cancer Symposium

Price target decreased to US$24.00

Insufficient new directors

Celcuity Inc. Appoints Polly A. Murphy to its Audit Committee and Its Compensation Committee

Celcuity Inc. to Report Q3, 2022 Results on Nov 10, 2022

Celcuity Inc. Appoints Polly Murphy to Board of Directors

Is Celcuity (NASDAQ:CELC) A Risky Investment?

Celcuity Inc. to Report Q2, 2022 Results on Aug 11, 2022

Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment

Insufficient new directors

Price target decreased to US$30.50

Celcuity Inc. to Report Q1, 2022 Results on May 16, 2022

Celcuity Inc., Annual General Meeting, May 12, 2022

Is Celcuity (NASDAQ:CELC) A Risky Investment?

Health Check: How Prudently Does Celcuity (NASDAQ:CELC) Use Debt?

Celcuity: Nipping The Oncogenic Bud

Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

What You Need To Know About Celcuity Inc.'s (NASDAQ:CELC) Investor Composition

New 90-day high: US$17.80

New 90-day high: US$14.95

Celcuity Inc. Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen

We're Hopeful That Celcuity (NASDAQ:CELC) Will Use Its Cash Wisely

New 90-day high: US$11.97

Celcuity inks clinical trial pact with Massachusetts General Hospital and Puma Technologies

Could The Celcuity Inc. (NASDAQ:CELC) Ownership Structure Tell Us Something Useful?

New 90-day high: US$6.55

Celcuity EPS beats by $0.03

Celcuity Inc. to Report Q2, 2020 Results on Aug 10, 2020

Celcuity Inc.(NasdaqCM:CELC) dropped from Russell 2000 Dynamic Index

Celcuity Inc.(NasdaqCM:CELC) dropped from Russell Small Cap Completeness Index

Celcuity Inc.(NasdaqCM:CELC) dropped from Russell 3000 Growth Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘